You have read all your free articles, to continue reading subscribe to read the rest of this content.
Gilead Sciences and Novo Nordisk have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). The companies will conduct a phase 2b double-blind, placebo-controlled study to investigate the safety and efficacy of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, and aAlready a subscriber Login You have read all your free articles,…
Nordic Nanovector have announces initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for stem cell transplantation. The initial results from the completed Phase I study (n=16 treated with BetalAlready a subscriber Login You have read all your…
Novo Nordisk has announced that Victoza (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence interval [CI]: 0.78; 0.97, p=0.01), when added to Already a subscriber Login You have read all…
BerGenBio has announced that bemcentinib has been selected as the first potential treatment to be fast-tracked in a new UK national multi-centre randomized Phase II clinical trial initiative. The ACcelerating COVID-19 Research & Development platform (ACCORD) study is being funded by the DeparAlready a subscriber Login You have read all…
